Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Radium-223,Niraparib Tosylate
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Bayer to Present Data from Growing Oncology Portfolio at the ASCO20 Virtual Scientific Program
Details : Presentation showcases data on final analysis of overall survival (OS) from the Phase III ARAMIS trial investigating darolutamide in men with non-metastatic castration-resistant prostate cancer.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
November 05, 2020
Lead Product(s) : Radium-223,Niraparib Tosylate
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable